Several studies have demonstrated supplementing "at risk" high cholesterol groups with magnesium reduces bad cholesterol levels. In some studies the reduction of cholesterol is quite significant even with modest amounts of magnesium (400-800 mg per day) usually as a supplement.
Unfortunately, there have not been any long-term studies to see if supplementation with magnesium does reduce the risk of heart disease or stroke.
In this study magnesium use as the nutrient.
What about use magnesium for decrease Cholesterol in clinical practice?
According to the present study only in nephropathies a beneficial effect was seen
We conclude that patients with chronic kidney disease undergoing MHD show positive correlation between serum Mg and serum HDL, LP-a and TG. The abnormalities of lipid metabolism, such as hyper-triglyceridemia, elevated LP-a and low HDL-c, could contribute to atherosclerosis and cardiovascular disease in these patients.
https://www.ncbi.nlm.nih.gov/pubmed/22237213
Thanks a lot Luis for your answer!
Good work and interesting results.
Are you treatment those patients with statins?
Often patients with end stage renal dysfunction has high level of TCh and TG.
Thanks a lot for your comment.
This data show no benefit magnesium intake in AMI patients. But my question not addressed to those patients.
If we talk about patients with AMI little data available about using magnesium additional to GIK. Unfortunately all those study no show limitations of infarct size and not improve clinical endpoint. In our country 15 years ago we use GIK+Mg, but after publications results CREATE-ECLA and DIGAMI 2 we stop to treatment (corrected by SK).
But I have no data to study cholesterol in RCT with medications like magnesium.
There are no such data. I have been at the forefront of magnesium-related research and therapy for over two decades.
Magnesium is not used as part of GIK infusion. Try to think hard and long before responding.
All I can say is, keep trying if you must????!!!!
Thanks a lot Vinod for your comment. I agree that Mg not used in CREATE-ECLA and DIGAMI 2 study. But as I write in previous answer we have little experience to use Mg additional to GIK in AMI patients. Yes, we do not have benefit to infarct size benefit end clinical outcome.
But first of all my question was not about patients with AMI, please be careful to answer on main question. I do not planing any study with MG in AMI patients. As for me it is enough data according evidence based medicine no benefit Mg in AMI patients.
Additional information. I ask this question because:
cardiomagnyl included two active material: acetylsalicylic acid 75 mg and magnesium hydroxide 15.2 mg. Part of the cardiomagnyl - magnesium hydroxide protect the gastrointestinal mucosa against acetylsalicylic acid.
It is small dose of magnesium hydroxide, but if we have any relations between magnesium intake and level of colesterol (with or without statins).
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Medical Pharmacology
- Clinical Pharmacology